News
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
TSIS 2010, March 9-13, Munich, Germany
February 18 2010
ToxExpo, March 7-11, Salt Lake City, Utah
February 16 2010
CRITICARE 2010, February 10-14, Hyderabad, India
January 25 2010
SCCM Annual Congress, January 9-13, Miami Beach, Florida
January 07 2010
BioPorto Diagnostics and ALPCO Diagnostics enter into partnership
December 02 2009
Product launch: Dog NGAL ELISA Kit (KIT 043)
November 16 2009
MEDICA, November 18-21, Düsseldorf, Germany
November 09 2009
BioPorto introduces The NGAL Test at the ASN Renal Week 2009, October 27 – November 1, San Diego
October 16 2009
Breakthrough test can prevent fatal kidney failure
September 21 2009
Product launch: Mouse NGAL ELISA Kit (KIT 042)
July 07 2009 by Ana Belén Enfedaque Buisán
BioPorto Diagnostics has launched an ELISA test for the determination of the acute kidney injury marker NGAL in mice. NGAL determination allows kidney injury to be detected almost as soon as it occurs and not just at the later stage when the consequences of damage have set in with impaired kidney function or actual failure.
Mice are among the most frequently used laboratory animals and often used in early research and development of potential drug treatments and the Mouse NGAL model has previously shown great promise. The Mouse NGAL Kit complements the NGAL product line and serves as an alternative to the rat model when assessing kidney damage as a result of nephrotoxic or ischemic events.
Therefore NGAL measurement in mice could prove to be of considerable value in the preclinical evaluation of new pharmacological products, as it is much cheaper and easier to determine NGAL than to carry out the typical microscopic examination of the kidney itself. BioPorto Diagnostics’ expectations are supported by a rather constant demand for animal NGAL ELISAs since the launch of the first human NGAL ELISA Kit.
The Mouse NGAL test can thus be used early in the development of new treatments for kidney damage, to detect nephrotoxic side effects of new drugs, and for basic science research on kidney injury and kidney diseases.
BioPorto Diagnostics’ expectations are supported by an incipient demand for animal NGAL ELISAs from the pharmaceutical industry and the CROs (Contract Research Organizations) that carry out the majority of the industry’s testing, as well as from large publicly-funded international research institutions.
Click here to go to the NGAL (mouse, neutrophil gelatinase-associated lipocalin) product page
